Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?

Cancers (Basel) · 2022 · PMC9139752 · PMID 35625957

Europe PMC DOI

hedged sentences

0.0620

closest p · 1.2× alpha

0.0705

boldest claim

The sentences

borderline significantp = 0.0620so close (0.05 < p ≤ 0.1)

While the SLFN11 H-score assessed in cancer cells showed only a borderline significant association (HR = 0.62, 95% confident interval (CI) = 0.38–1.02, p = 0.0620), overall and non-cancer higher SLFN11 H-scores were strongly associated with longer progression-free interval (PFI) by univariable analysis (HR = 0.50, 95% CI = 0.33–0.75, p = 0.0009; and HR = 0.54, 95% CI = 0.36–0.81, p = 0.0028, respectively).

also in 11,409 other papers

did not reach statistical significancep = 0.0705so close (0.05 < p ≤ 0.1)

Consequently, the differences between median PFI in SLFN11-high patients (14 months) and SLFN11-low patients (6 months) did not reach statistical significance ( p = 0.0705).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.